LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com

LivaNova (NASDAQ:LIVN) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday.

Other equities analysts also recently issued reports about the company. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. Mizuho lowered their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group started coverage on shares of LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $69.17.

LivaNova Price Performance

NASDAQ LIVN remained flat at $47.63 on Wednesday. The company had a trading volume of 554,533 shares, compared to its average volume of 468,526. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of 113.40 and a beta of 0.98. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova has a 1-year low of $43.15 and a 1-year high of $64.47. The business has a fifty day moving average price of $49.74 and a 200 day moving average price of $50.20.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

A number of large investors have recently modified their holdings of the company. Canada Pension Plan Investment Board bought a new stake in LivaNova during the 2nd quarter valued at $88,000. Central Pacific Bank Trust Division acquired a new position in shares of LivaNova during the third quarter valued at about $178,000. Captrust Financial Advisors bought a new stake in shares of LivaNova during the third quarter worth about $217,000. Sanctuary Advisors LLC acquired a new stake in shares of LivaNova in the 3rd quarter worth about $219,000. Finally, Edgestream Partners L.P. bought a new position in LivaNova in the 3rd quarter valued at about $244,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.